Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
16 nov. 2023 07h00 HE
|
LAVA Therapeutics N.V.
LAVA-1207 in mCRPC continues Phase 1/2a dose escalation study in monotherapy arm and in combination with IL-2Seagen initiated a Phase 1 study of SGN-EGFRd2 (LAVA-1223) to evaluate the safety and...
LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
06 sept. 2023 07h11 HE
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, Sept. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™...
LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
22 août 2023 07h00 HE
|
LAVA Therapeutics N.V.
Significant progress with lead program LAVA-1207 in mCRPC reaching dose level 8Significant progress with collaborators including selection of lead candidate by Janssen Biotech and IND clearance for...
LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual Conference
14 août 2023 07h00 HE
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA , Aug. 14, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused on developing its proprietary Gammabody®...
LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway
14 juin 2023 09h00 HE
|
LAVA Therapeutics N.V.
• LAVA-1207 for the treatment of prostate cancer will continue as the lead program• LAVA-051 Phase 1/2a clinical trial will be discontinued• Associated cost savings and initiatives are expected to...
LAVA Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
08 juin 2023 07h00 HE
|
LAVA Therapeutics N.V.
Lead development candidate selected by Janssen Biotech under research collaboration provides a milestone payment to LAVAStrong balance sheet expected to provide cash runway into 2026 UTRECHT, The...
LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical Development
01 juin 2023 16h20 HE
|
LAVA Therapeutics N.V.
Through a research collaboration with Janssen, a lead candidate was identified for further development towards clinical studies.In May 2020, LAVA entered into a research collaboration and license...
LAVA Therapeutics to Participate in the Jefferies Healthcare Conference
01 juin 2023 08h09 HE
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, June 01, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™...
LAVA Announces Annual Meeting of Shareholders
30 mai 2023 17h28 HE
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, May 30, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX) (LAVA), a clinical-stage immuno-oncology company focused on developing its...
LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results
11 avr. 2023 07h00 HE
|
LAVA Therapeutics N.V.
Initial clinical data for LAVA-051 suggest a favorable safety profile and initial anti-tumor activity in the ongoing dose escalation Phase 1/2a clinical trial in patients with relapsed and refractory...